Physician profile
Ashley Mcgehee
NPI 1669255543
$2,174.46
in general payments reported to CMS, 2019-2025
16 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $804 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $409.47 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $391.77 | 2024-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $341.78 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $185.22 | 2024-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $174.89 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $143.23 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.37 | 2024-2025 | Trintellix |
| Dexcom, INC. | $88.13 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $81.59 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $59.09 | 2024-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.22 | 2024-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.13 | 2024-2025 | Xifaxan, Trulance |
| Pfizer INC. | $41.79 | 2025 | |
| Phathom Pharmaceuticals, INC. | $30.78 | 2025 | Voquezna |
| Astellas Pharma US INC | $21.55 | 2025 | Veozah |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $21.45 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mcgehee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.